Rubric Capital Management LP holds $1.55M position in Immunovant, Inc. (NASDAQ:IMVT)

Rubric Capital Management LP acquired a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) in the 2nd quarter, Holdings Channel reports. The fund acquired 58,624 shares of the company’s stock, valued at approximately $1,548,000.

Several other hedge funds and other institutional investors have recently made changes to their positions in IMVT. Assetmark Inc. purchased a new stake in shares of Immunovant during the fourth quarter valued at approximately $61,000. Quest Partners LLC raised its position in shares of Immunovant by 216.7% in the second quarter. Quest Partners LLC now owns 2,610 shares of the company’s stock valued at $69,000 after purchasing an additional 1,786 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Immunovant during the 2nd quarter valued at about $77,000. EntryPoint Capital LLC increased its position in shares of Immunovant by 288.8% in the first quarter. EntryPoint Capital LLC now owns 2,912 shares of the company’s stock valued at $94,000 after buying an additional 2,163 shares in the last quarter. Finally, DNB Asset Management AS boosted its position in shares of Immunovant by 10.3% in the second quarter. DNB Asset Management AS now owns 10,290 shares of the company’s stock valued at $271,000 after purchasing an additional 958 shares in the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s shares.

Changes in Analyst Ratings

Several equities research analysts recently commented on IMVT shares. JPMorgan Chase & Co. cut their price target on shares of Immunovant from $51.00 to $46.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Oppenheimer cut their price target on shares of Immunovant from $50.00 to $46.00 and set an “outperform” rating for the company in a report on Monday, June 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunovant in a report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $51.00 target price on shares of Immunovant in a report on Tuesday, September 10th. Finally, UBS Group cut their price target on Immunovant from $42.00 to $41.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Fifteen research analysts have rated the stock with a buy rating. The company presently has a consensus rating of “Buy” and a consensus price target of $48.40, according to MarketBeat.

Check out the latest stock report on IMVT

Insider Trading at Immunovant

In other news, CFO Eva Renee Barnett sold 4,747 shares of the company’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $28.06, for a total transaction of $133,200.82. Following the sale, the chief financial officer now owns 350,667 shares in the company, valued at $9,839,716.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this hyperlink. In related news, CEO Peter Salzmann sold 8,685 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $29.69, for a total value of $257,857.65. Following the sale, the chief executive officer now owns 1,023,412 shares in the company, valued at $30,385,102.28. The sale was disclosed in a legal filing with the SEC, which is available via this link. Also, CFO Eva Renee Barnett sold 4,747 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $28.06, for a total value of $133,200.82. Following the completion of the sale, the chief financial officer now owns 350,667 shares in the company, valued at approximately $9,839,716.02. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,475 shares of company stock worth $904,638. Insiders own 5.90% of the company’s shares.

Immunovant trading down 1.2%

Shares of Immunovant stock opened at $29.23 on Friday. The firm has a market cap of $4.27 billion, a P/E ratio of -15.38 and a beta of 0.67. Immunovant, Inc. has a 12-month low of $19.50 and a 12-month high of $45.58. The stock’s fifty day moving average price is $29.85 and its 200 day moving average price is $29.35.

Immunovant (NASDAQ:IMVT – Get Your Free Report ) last posted its earnings results on Tuesday, August 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.07). In the same quarter last year, the firm posted ($0.57) earnings per share. Analysts estimate that Immunovant, Inc. will record -2.43 earnings per share for the current year.

About Immunovant

(Free Report)

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. She is developing batoclimab, a novel fully human monoclonal antibody targeting the crystallizable neonatal fragment receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy and Graves’ disease, as well as warm autoimmune hemolytic anemia.

Featured stories

Want to see what other hedge funds hold IMVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Immunovant, Inc. (NASDAQ:IMVT – Free Report).

Get news and reviews for Immunovant Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Immunovant and related companies with MarketBeat.com ‘s FREE daily email newsletter.